Forest Laboratories (FRX) 'Day of Reckoning' Not Far Off

April 22, 2013 3:31 PM EDT Send to a Friend
Get Alerts FRX Hot Sheet
Price: $99.00 --0%

Rating Summary:
    10 Buy, 16 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade FRX Now!
Join SI Premium – FREE
Forest Laboratories (NYSE: FRX) is set to report Q4 earnings on Tuesday morning. In the view of analyst Jami Rubin of Goldman Sachs, investors will be less concerned about 4Q EPS and more interested in the progress of several new product launches.

"As we have been saying, FY2014 will be the year of reckoning for the company. If new product launches continue to be disappointing, or if earnings estimates continue to be ratcheted down as they were in FY 2013, we believe that management will have to consider a Plan B (i.e, restructuring, strategic alternatives), or the shares will likely underperform," said Rubin.

Goldman Sachs has a Neutral rating on Forest Laboratories with a price target of $40.00.

For an analyst ratings summary and ratings history on Forest Laboratories (NYSE: FRX) click here. For more ratings news on Forest Laboratories click here.

Shares of Forest Laboratories closed at $35.91 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Goldman Sachs, Earnings

Add Your Comment